Quimioterapia de elección tras hormonoterapia en cáncer de mama metastásico - page 2

RWD in Spanish population: the CASCADE study

Zamora et al SABCS 2015. P3-07-37

•

Dramatic differences PFS observed in initial lines (TN-worse performing group)

•

Median OS

(whole study)

32.8 mo (HR+HER2- median OS 38.6 mo vs TN 19 mo)

SEO Version

Warning.

You are currently viewing the SEO version of !text.
It has a number of design and functionality limitations.

We recommend viewing the Flash version or the basic HTML version of this publication.

1 3,4,5,6,7,8,9,10,11,12,...36